The FDA’s approval of KEYTRUDA QLEX™ for subcutaneous use marks a significant advancement in cancer treatment, offering patients a more convenient administration option. This development not only enhances patient experience but also reinforces Merck’s position in the competitive oncology market.
RAHWAY, N.J.–(BUSINESS WIRE)—- $MRK #MRK–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous administration in adults across most solid tumor indications for KEYTRUDA® (pembrolizumab). Berahyaluronidase alfa is a variant of human hyaluronidase developed and manufactured by Alteogen Inc. KEYTRUDA QLEX must be administer
Source: Original Press Release
